TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06097026
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administer nitric oxide upon arrival from cardiac surgery and assess cardiac and pulmonary function afterwards.
Study: NCT05882812
Drug: 2.5% Diclofenac Patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.
Study: NCT05265208
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will given at 1250mg/m², 2 times a day with an interval of about 12 hours between two intakes, 2 weeks on, 1 week off, for 4 pre-surgery cycles.
Study: NCT04853355
Drug: Spironolactone 50 mg
Normalized name: spironolactone 50 MG
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Add Spironolactone 50 mg to previous regimen
Study: NCT05282069
Drug: DA-8010 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive placebo to match DA-8010 orally once a day.
Study: NCT05282069
Drug: DA-8010 2.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive DA-8010 2.5mg orally once a day.
Study: NCT06151444
Drug: Alpha-Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
Study: NCT06151444
Drug: α-adrenergic receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
Study: NCT05361824
Drug: Ketorolac Injection
Normalized name: ketorolac Injection
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dosage form: intravenous dosage: 30mg frequency: 8 hours apart (TDS) duration: for 48 hours post operatively
Study: NCT06139744
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is orally supplemented with one tablet each day before morning, lunch and dinner, and placebo does not contain dehydrated pea seedling powder 4.2mg.
Study: NCT06437262
Drug: 0.20% CHX gel on saliva
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vivo application of a gel on the vestibular and palatal/lingual gingival mucosa of both arches at minute 0 for posterior saliva collection at different time-points.
Study: NCT06437262
Drug: 0.20% CHX and Cymenol gel on saliva
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vivo application of a gel on the vestibular and palatal/lingual gingival mucosa of both arches at minute 0 for posterior saliva collection at different time-points.
Study: NCT06437262
Drug: 0.20% CHX gel on oral biofilm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ex vivo application of a gel on the glass disks of the removable intraoral appliance at minute 0 for subsequent one-by-one disk removal from the device at different time-points.
Study: NCT06437262
Drug: 0.20% CHX and Cymenol gel on oral biofilm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ex vivo application of a gel on the glass disks of the removable intraoral appliance at minute 0 for subsequent one-by-one disk removal from the device at different time-points.
Study: NCT04275778
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo will be taken at a dosage of 400 mg / day until delivery
Study: NCT06081686
Drug: Phase II:[177Lu]Lu-XT033 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received \[177Lu\]Lu-XT033 Injection every 8 weeks (+/- 1 week) for a maximum of 6 cycles.
Study: NCT05159999
Drug: Anti-hypertensive medications
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-hypertensive medications will be adjusted every 2 weeks to reach the home or pre-dialysis systolic blood pressure target. Adjustment of currently prescribed anti-hypertensive medications will be prioritized before starting new medications. Only standard anti-hypertensive medications will be used, such as RAAS inhibitors, beta-blockers, calcium channel blockers and diuretics.
Study: NCT04558112
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: two gel capsules of placebo
Study: NCT05905913
Drug: ANT3310
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANT3310 will be infused over 3 hours
Study: NCT05905913
Drug: ANT3310-placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANT3310-placebo will be infused over 3 hours
Study: NCT05905913
Drug: ANT3310
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANT3310 will be infused over 3 hours every 8 hours
Study: NCT05905913
Drug: ANT3310-placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANT3310-placebo will be infused over 3 hours every 8 hours
Study: NCT05905913
Drug: ANT3310-placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANT3310-placebo will be infused over 3 hours as a single dose as part of the drug drug interaction study, then every 8 hours as part of the repeat doses study.
Study: NCT05905913
Drug: ANT3310
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANT3310 will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.
Study: NCT05266612
Drug: VG2025
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. 1.0×108PFU Day 1 and 15~2. 2.0×108PFU Day 1 and 15~3. 3.0×108PFU Day 1 and 15~4. 4.0×108PFU Day 1 and 15
Study: NCT05263960
Drug: CM350_group 5b
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM350 will be administered intravenously (IV) once a week (QW). Patients will take 135ug of CM350 on the first day of first cycle (C1D1), 135ug on C1D8, 135ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study: NCT05263960
Drug: CM350_group 6b
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM350 will be administered intravenously (IV) once a week (QW). Patients will take 135ug of CM350 on the first day of first cycle (C1D1), 270ug on C1D8, 270ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study: NCT05263960
Drug: CM350_group 7
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM350 will be administered intravenously (IV) once a week (QW). Patients will take 135ug of CM350 on the first day of first cycle (C1D1), 405ug on C1D8, 405ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study: NCT05263960
Drug: CM350_group 8
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM350 will be administered intravenously (IV) once a week (QW). Patients will take 405ug of CM350 on the first day of first cycle (C1D1), 405ug on C1D8, 405ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study: NCT06264739
Drug: esp remifentanyl (ultiva)
Normalized name: remifentanil Injection [Ultiva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: After anesthesia and surgical procedures, bilateral ESP block will be applied under ultrasonography guidance from the midline 3 cm lateral from the T10 level. After cleaning the area with povidone-iodine before the block, the T10 transverse protrusion will be determined using a linear ultrasound probe. Local anesthetic will be applied between the transverse process and the erector spinae muscle with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection with physiological saline without local anesthesia. After the location of the needle is confirmed, 20 ml of LA and saline mixture will be applied and the same process will be repeated in the contralateral side. Of the total 40 ml LA, 20 ml will consist of bupivacaine 0.5% (marcaine), 10 ml will consist of lidocaine 2% (aritmal), and 10 ml will consist of physiological saline.
Study: NCT06369974
Drug: Antisense oligonucleotide treatment (ASO)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: nL-TUBB4-001; Personalized antisense oligonucleotide
Study: NCT05497089
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given as monthly (every 4 weeks) intravenous (IV) infusion over 24 weeks (6 infusions in total)
Study: NCT04946890
Drug: MRX2843
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRX2843 is treated at 80mg/d, 120mg/d and 180mg/d respectively
Study: NCT00992238
Drug: Urispas® Tablets, 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05906836
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally.
Study: NCT05493462
Drug: Human FGF-1
Normalized name: herpesvirus 1, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal administration of human FGF-1
Study: NCT04893980
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: During Day 0-14, patients in the control group receive treatment with only antihistamines at the same dosage as pre-recruitment, but no injection of rhIL-2. During Day 15-28, treatment with low dose recombinant human Interleukin-2 (rhIL-2), i.e., 1 million international units every other day by subcutaneous or intramuscular injection (rhIL-2, 1MIU, im, Qod), will be added.
Study: NCT05057663
Drug: Bleomycin and 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the bleomycin-treated group, bleomycin vial will be diluted first with 5 ml distilled water At time of treatment session 2 ml of lidocaine 2% and 1 ml of the bleomycin stock solution will be taken in 100-unite insulin syringe. Thus, the working bleomycin solution will be used in treatment 1 mg/ml. The bleomycin solution will be injected intralesional till blanching of the wart will be occurred. The amount of injection ranging from 0.2, 0.5, 1 ml according to size of warts; (5 mm, 10 mm, \>10 mm) maximum for 1 ml in single wart and 2ml in treatment session. Treatment session will be done every two weeks maximum four sessions.~In 5-fluorouracil treated group, 5-fluorouracil vial ( 1 ml of 50 mg/ml 5-FU will be mixed with 0.25 ml of lidcaine 2% Every wart will be injected with 0.1 ml of the previous mixture into it base using an insulin syringe till blanching of the warts maximum 2ml of 5-FU per session. Treatment session will be done every two week for maximum 6 sessions
Study: NCT05214287
Drug: Hypoxic Gas Mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using a commercially available hypoxicator, varying gas mixtures as described will be administered via a tight-fitting oxygen mask. In the circuitry, a three-way valve is placed that allows for the intermittent administration of hypoxia: the valve either passes the hypoxic mixture from the hypoxicator or room air.
Study: NCT04708340
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodium Chloride in Water for Injection a.k.a. Normal Saline for injection
Study: NCT06727422
Drug: rifaximin 66mg + N-acetylcysteine 560mg three times daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: RNIB21 containing rifaximin 66mg + N-acetylcysteine 560mg three times daily
Study: NCT06727422
Drug: RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily
Study: NCT06727422
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo three times daily
Study: NCT05863195
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05863195
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05506943
Drug: CTX-009
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion on day 1 and 14 of every 28 day cycle
Study: NCT05284656
Drug: combination of Pentoxifylline 400 MG and Folic Acid
Normalized name: pentoxifylline 400 MG
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: drugs used to delay progression of chronic kidney disease
Study: NCT05284656
Drug: folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: drugs used to delay progression of chronic kidney disease
Study: NCT06478563
Drug: NNC0487-0111 (formulation D)
Normalized name: Rho(D) - Unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive NNC0487-0111 (formulation D) tablet once daily.
Study: NCT05958849
Drug: Sovalteinib Solutumab Tegeo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soventinib in combination with solutumab and tegeo for advanced pancreatic cancer
Study: NCT00000635
Drug: Bacitracin zinc/Polymyxin B sulfate
Normalized name: bacitracin zinc/polymyxin B sulfate/pramoxine TOPICAL OINTMENT (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06089278
Drug: TQH2722 injection matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo without active substance.
Study: NCT05135013
Drug: Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: History of hormonal use as follows:~1. Reason for hormonal use: contraception, fertility promotion, Polycystic ovary syndrome (PCOS)~2. Duration of hormonal use~3. Type of hormonal drug used: dose, hormone type, route of administration
Study: NCT06471088
Drug: Dovprela
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose: 200 mg
Study: NCT05754853
Drug: MRG002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated intravenously
Study: NCT06673602
Drug: FCYC+Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment combined with oral administration of FCYC (four capsules, three times a day, orally) for a 12-week course of treatment.
Study: NCT06673602
Drug: conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group will receive the current gold standard treatment for ICH according to the guidelines (AHA/ASA 2022). This involves blood pressure and care.
Study: NCT00254319
Drug: Avastin, Alimta
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05927844
Drug: XH-30002 capsule
Normalized name: TRENBOLONE ACETATE 200 mg / ESTRADIOL 20 mg SUBCUTANEOUS IMPLANT [Revalor XH]
Approvals — FDA: no, EMA: no, PMDA: no
Description: receive the study drug until the investigator assessed no longer benefit, toxic intolerance, withdrawal of consent, loss of follow-up, or death, whichever occurred first
Study: NCT05573191
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT05003570
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage forms and strengths: 3 mL Vial/1 mg lyophilized powder. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
Study: NCT05003570
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosage forms and strengths: 50 mcg/mL Fentanyl base/10 mL ampules. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
Study: NCT06235567
Drug: Dextenza 0.4Mg Ophthalmic Insert
Normalized name: Dextenza 0.4mg Ophthalmic Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: This insert allows for sustained release of dexamethasone onto the ocular surface over a period of 28 days. It requires a single application and eliminates the potential for noncompliance, difficulty in administration and poor accuracy. Dextenza has been FDA approved for post-operative pain and inflammation following ophthalmic surgery. The pivotal trials included patients undergoing cataract surgery, not CXL surgery. In addition, the age range did not include those of pediatric age.
Study: NCT06235567
Drug: topical prednisolone acetate 1% (PredForte) eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will administer the anti-inflammatory steroid drops on the same 4 week post-operative schedule that is commonly used in standard of care. They will do one drop of Pred Forte in the affected eye 4 times a day for a week, 3 times a day for the second week, 2 times a day for the third week, and once a day for the fourth week.
Study: NCT04890379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 240mg orally twice daily for 3 consecutive days
Study: NCT05707871
Drug: SPECTRUM cigarettes
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPECTRUM cigarettes have varying amount of nicotine content
Study: NCT05371288
Drug: NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements hypothesized to help reverse some of the COVID long-haul symptoms.
Study: NCT04935073
Drug: Prescription of traditional Chinese Medicine named Er Zhi Wan combined with Si Wu Tang
Approvals — FDA: no, EMA: no, PMDA: no
Description: The medicines used in this study including Radix et Rhizoma Ligustrum 15 g, Radix Morindae Sinensis 12 g, Fructus Lycii 15 g, Semen Cuscutae 20 g, Radix Rehmanniae 15 g, Radix Angelicae Sinensis 10 g, Radix Paeoniae Alba 10 g, Ligusticum wallichii 6 g, Poria cocos 15g, Polygonatum 15g, eclipta 10g. which will be taken for 10-15days.After the ET, the treatment group will continue to take Chinese herbal medicine, changing to Shou Tai pills ( Morinda officinalis 15 g, Teasel 15g，Cuscutae 20 g, Eucommia ulmoides 15 g, Rehmannia 15 g, Cornus officinalis 15 g, loranthus parasiticus 20 g, Ligustrum lucidum 15g, Salvia miltiorrhiza 10g, Scutellaria baicalensis 10g, Atractylodes macrocephala 15g); which will be taken for 14days. The hospital will be responsible for the decoction of 200 mL per dose, 1 dose per day, divided into 2 doses in the morning and in the evening.
Study: NCT05266417
Drug: Matched Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Matched Placebos Twice Daily
Study: NCT05045261
Drug: Discontinuation of NUC treatment in arms B and C
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUC treatment will be stopped after 28 weeks in arms B and C
Study: NCT04589130
Drug: Contrave 8Mg-90Mg Extended-Release Tablet
Normalized name: Contrave 8mg-90mg Extended-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each Contrave Extended Release Tablet contains 8Mg of naltrexone HCl and 90Mg of bupropion HCl and will be administered orally. Total daily dose is 32Mg / 360Mg.~Participants randomized to the treatment arm will be administered 4 Contrave tablets a day for 1 year (2 tablets taken twice a day).~Participants randomized to the control arm for the first 6 months will crossover and be administered 4 Contrave tablets a day during the second 6 months (2 tablets taken twice a day). All participants will be in the treatment group (Contrave) during the second 6 month phase of the study.
Study: NCT04589130
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be administered orally. Participants randomized to the control arm will be administered 4 placebo tablets a day (2 tablets, taken twice a day) during the first 6 months of the study. These participants will crossover to treatment with Contrave for the second 6 months of the study.
Study: NCT06006650
Drug: Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
Study: NCT05184517
Drug: Oph1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% CsA ophthalmic formulation, twice daily for 4 days and once on the fifth day, one eye (right).
Study: NCT05001945
Drug: MLS-101 (Part I)
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLS-101 tablet(s) by mouth once or twice daily.
Study: NCT05001945
Drug: MLS-101 (Part II)
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLS-101 tablet(s) by mouth once daily.
Study: NCT05067387
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo
Study: NCT05067387
Drug: THC + CBD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral THC (20 mg) + CBD (20 mg)
Study: NCT05325853
Drug: Proparacaine Ophthalmic
Normalized name: proparacaine ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% Proparacaine Hydrochloride
Study: NCT04964557
Drug: AZD8233
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
Study: NCT04964557
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution
Study: NCT04805073
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1cc 0.9% Sodium Chloride (placebo)
Study: NCT05062577
Drug: ASP8062
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT05062577
Drug: Placebo ASP8062
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT06577597
Drug: GSK3923868
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single dose of GSK3923868.
Study: NCT06577597
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single dose of Placebo.
Study: NCT04974957
Drug: SHR-1701；BP102
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: SHR-1701 IV infusion~Drug: BP102 IV infusion
Study: NCT05441267
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral semaglutide
Study: NCT05399329
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib plus ET as first-line/second-line treatment for HR+/HER2- ABC
Study: NCT05032937
Drug: domestic polysaccharide superparamagnetic iron oxide nanoparticle
Normalized name: iron oxide, nanoparticles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before percutaneous coronary angiography.Patients received intravenous polysaccharide superparamagnetic iron oxide nanoparticle before magnetic resonance imaging.
Study: NCT05173896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of oral over-encapsulated placebo tablets for three months.
Study: NCT06726564
Drug: MT027 cells suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT027: CRISPR/Cas9 edited B7H3-specific allogeneic CAR-T cells
Study: NCT06725992
Drug: IY-NS250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 20mg + Sodium bicarbonate 500mg